Impact of COVID-19 on chronic disease management
DOI:
https://doi.org/10.18203/2320-6012.ijrms20213110Keywords:
Routine care, Chronic diseases, COVID-19, Healthcare professionals, DiabetesAbstract
Routine care for chronic disease is an ongoing major challenge. We aimed to evaluate the impact of COVID-19 on routine care for chronic diseases. A deeper understanding helps to increase the health system’s resilience and adequately prepare for the next waves of the pandemic. Diabetes, heart failure, chronic kidney disease, and hypertension were the most impacted conditions due to the reduction in access to care. It is important routine care continues in spite of the pandemic, to avoid a rise in non-COVID-19-related morbidity and mortality. This is a review article discussing the potential impact of COVID-19 on chronic disease management.
Metrics
References
Xie J, Wu W, Li S, Hu Y, Hu M, Li J et al. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Med. 2020;46(10):1863-72.
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12(7):6049-57.
The Lancet Respiratory M. COVID-19 heralds a new era for chronic diseases in primary care. Lancet Respir Med. 2020;8(7):647.
Alba A, Frankfurter C, Buchan T, Kobulnik J, Luk A, McDonald M et al. Reduced rate of hospital presentations for heart failure during the COVID-19 pandemic in Toronta, Canada. Can J Cardiol. 2020;36(10):S74.
Papafaklis MI, Katsouras CS, Tsigkas G, Toutouzas K, Davlouros P, Hahalis GN, et al. "Missing" acute coronary syndrome hospitalizations during the COVID-19 era in Greece: Medical care avoidance combined with a true reduction in incidence? Clin Cardiol. 2020;43(10):1142-9.
Cosentino N, Assanelli E, Merlino L, Mazza M, Bartorelli AL. An In-hospital Pathway for Acute Coronary Syndrome Patients During the COVID-19 Outbreak: initial Experience Under Real-World Suboptimal Conditions. Can J Cardiol. 2020;36(6):961-4.
Birkmeyer JD, Barnato A, Birkmeyer N, Bessler R, Skinner J. The Impact of The COVID-19 Pandemic On Hospital Admissions In The United States. Health Aff. 2020;39(11):2010-7.
Mesnier J, Cottin Y, Coste P, Ferrari E, Schiele F, Lemesle G, et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health. 2020;5(10):e536-42.
De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41(22):2083-8.
Almufleh A, Ahluwalia M, Givertz MM, Weintraub J, Young M, Cooper I, et al. Short-term Outcomes in Ambulatory Heart Failure during the COVID-19 Pandemic: insights from Pulmonary Artery Pressure Monitoring. J Card Fail. 2020;26(7):633-4.
COVID-19 Pulse: delivering regular insights on the pandemic from a 150,000+ person connected cohort. https://evidation.com/news/covid-19-pulse-first-data-evidation/. Accessed on 25th January, 2021.
Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(10):1915-24.
Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2021;49(2):238-46.
Tam CF, Cheung KS, Lam S, Wong A, Yung A, Sze M et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020;13(4):e006631.
International. Costs and Rationing of Insulin and Diabetes Supplies: Findings from the 2018 T1International Patient Survey. https://www.t1i nternational.com/media/assets/file/T1International_Report_-_Costs_and_Rationing_of_Insulin__Diabetes_Supplies_2.pdf. Accessed on 20th April, 2020.
T1International. Statement on Insulin Manufacturer’s Responses to COVID-19. https://www.t1international.com/blog/2020/04/07/t1international-statement-eli-lillys-35-insulin/. Accessed on 21 April, 2020.
Dubey S, Biswas P, Ghosh R, Chatterjee S, Dubey MJ, Chatterjee S, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr. 2020;14(5):779-88.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-16.
Facts and Statistics International osteoporosis foundation. https://www.iofbonehealth.org/facts-statistics#category-14. Accessed on 24th May, 2020.
Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract. 2020;162:108132.
Boelaert K, Visser WE, Taylor PN, Moran C, Léger J, Persani L. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. Eur J Endocrinol. 2020;183(1):G33-9.
Connerney M, Sattar Y, Rauf H, Mamtani S, Ullah W, Michaelson N, et al. Delayed hemodialysis in COVID-19: Case series with literature review. Clin Nephrol Case Stud. 2021;9:26-32.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5):865-75.
Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183(7):1901-12.
Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5(8):776-87.
Downloads
Published
How to Cite
Issue
Section
